Methylene Blue: The Biohacker “Supplement” That Isn’t Really a Supplement

Methylene blue may have one of the strangest career trajectories in wellness.

It was synthesized in 1876 as a synthetic dye, originally for the textile industry. Its vivid color made it useful for staining cells and microorganisms under the microscope. Then, in 1891, Paul Ehrlich and Paul Guttmann used it to treat malaria, making it one of the earliest synthetic drugs.

Today, an injectable form is FDA-approved for acquired methemoglobinemia, a condition in which hemoglobin becomes less able to carry oxygen.

And now the same molecule has become a biohacking supplement.

People take low doses hoping to boost mitochondrial energy production, focus and memory, with some promoting it for brain aging and longevity.

The interest isn't entirely random. Methylene blue enters the brain, interacts with cellular redox pathways and has shown intriguing effects on mitochondrial function and cognition in experimental research.

It’s quite a trajectory: textile dye → laboratory stain → medicine → longevity supplement.

But methylene blue is still a pharmacologically active drug with meaningful drug interactions.. and the evidence for routinely taking it to improve cognition or slow aging is nowhere near the evidence supporting its established medical uses.

Why are biohackers so interested in it?

The longevity argument usually starts with mitochondria.

Mitochondria generate much of the cell’s usable energy through the electron transport chain, a series of proteins that move electrons and ultimately help produce ATP. Mitochondrial dysfunction is also one of the biological processes studied in aging and neurodegenerative disease.

Methylene blue is unusual because it is a redox-active molecule. It can cycle between oxidized methylene blue and its reduced form, leucomethylene blue, accepting and donating electrons under different conditions. In its approved medical use, this chemistry helps convert methemoglobin back toward functional hemoglobin.

Experimental research suggests the same redox properties can influence mitochondrial metabolism. In cultured human fibroblasts, for example, low concentrations of methylene blue altered several mitochondrial pathways.

This is where the longevity story begins, but it is also where people start to get ahead of the evidence.

Keeping fibroblasts dividing longer in a laboratory dish is not the same as slowing aging in a person, and changing mitochondrial function in cultured cells does not automatically increase human healthspan or lifespan.

There is currently no human evidence demonstrating that methylene blue extends lifespan or produces clinically meaningful slowing of biological aging.

The mitochondrial mechanism is also less settled than social media makes it sound

One of the biggest claims about methylene blue is that it can help mitochondria make more energy.

The theory goes like this: mitochondria normally move electrons through a series of protein complexes to produce ATP, the energy currency of the cell. Some researchers have proposed that methylene blue can act as an alternative electron carrier, essentially helping electrons move around a damaged or poorly functioning part of this system.

It is an appealing idea, but the evidence suggests it does not work that simply.

In experiments using isolated mouse brain mitochondria, for example, methylene blue could not bypass a blockage at one part of the energy-producing pathway known as complex III. Its effects seem to depend heavily on the dose, the tissue being studied, the metabolic conditions, and exactly where the mitochondrial problem occurs.

Dose may be especially important. Methylene blue appears to have a non-linear dose response, meaning more is not necessarily better. At one concentration it may affect metabolism one way, while a higher concentration can produce a different or even opposite effect.

A small 2023 human study shows why the simple “mitochondrial booster” label can be misleading.

Eight healthy women received intravenous methylene blue at two different doses. Researchers expected it to increase energy metabolism in the brain.

Instead, blood flow throughout the brain decreased by about 8%. Estimated brain oxygen use also fell by about 8% at the lower dose and nearly 12% at the higher dose. The researchers themselves noted that the results were the opposite of what they had expected.

This was a very small study, and the methylene blue was given intravenously rather than orally, so it cannot tell us what happens when healthy people take the oral doses commonly promoted online.

It also does not prove that methylene blue harms mitochondrial or brain function. What it does show is that saying “methylene blue boosts mitochondrial energy” is more confident than we see in the research.

What about the claims that it improves memory?

There actually is human evidence here.

A 2016 randomized, double-blind, placebo-controlled study enrolled 26 healthy adults between ages 22 and 62. Participants received a single oral dose of 280 mg methylene blue or placebo before undergoing cognitive testing and functional MRI.

Methylene blue altered activity in several brain regions involved in attention and short-term memory. Most notably, participants receiving methylene blue had about 7% more correct responses during a memory-retrieval task than those receiving placebo.

That is interesting.

It is not evidence that taking methylene blue every day improves cognition.

The study involved only 26 people, tested a single dose and primarily examined short-term cognitive performance and neuroimaging signals. It did not determine whether repeated methylene blue improves everyday memory, prevents cognitive decline or reduces dementia risk.

A related study from the same research program subsequently found changes in functional connectivity between brain regions after a single dose. Again, the result demonstrated a measurable effect on the brain, not a demonstrated long-term cognitive benefit.

A compound doing something in the brain is not the same as a compound improving brain health.

And Alzheimer's disease?

Methylene blue has also been studied in Alzheimer’s research because related compounds may interfere with tau, a protein that forms abnormal clumps in the disease.

That early research eventually led to a related drug called LMTM. But in a large phase 3 trial in people with mild to moderate Alzheimer’s disease, adding LMTM to standard treatment did not produce the expected clinical benefit.

LMTM is not the same as ordinary methylene blue, so this does not prove methylene blue has no neurological effects.

But it highlights an important point: changing an Alzheimer’s-related pathway in the lab is not the same as improving memory or slowing disease in people.

So while methylene blue remains scientifically interesting, claims that it can prevent or treat Alzheimer’s disease go well beyond the current evidence.

The biggest reason methylene blue is different from a normal supplement

Methylene blue may be sold in the same online spaces as longevity supplements, but pharmacologically, it behaves much more like a drug.

Most importantly, it inhibits MAO-A, an enzyme involved in breaking down serotonin. That means it can interact with medications that also raise serotonin, including many antidepressants and some opioids. The FDA-approved methylene blue product carries a boxed warning for serotonin syndrome, a potentially dangerous buildup of serotonin in the nervous system.

It can also cause severe red-blood-cell breakdown in people with G6PD deficiency and carries pregnancy-related warnings.

The risk from the low oral doses used by biohackers is less well defined than the risk from medical intravenous dosing. But these are still meaningful drug-like interactions, not the usual considerations that come with adding another vitamin or nutrient to a supplement stack.

So is methylene blue a longevity compound?

At the moment, that claim is getting ahead of the evidence.

Methylene blue has legitimate biological properties that make it scientifically interesting. It interacts with cellular redox systems. It can alter mitochondrial pathways. Laboratory studies have reported effects on cellular senescence. Animal research has generated intriguing neuroprotective findings. And one small randomized human study found a short-term improvement in a memory-retrieval task.

But we have not demonstrated that taking methylene blue makes healthy people cognitively sharper over the long term, prevents dementia, slows biological aging or extends human lifespan.

And unlike many compounds that enter longevity culture, methylene blue brings substantial pharmacology with it.

That is what makes the trend so interesting.

Biohacking culture has taken a drug with unusual mitochondrial and neurological effects and repositioned it to look like a supplement.

The research is interesting enough to keep studying, but not strong enough to recommend it yet.